指南与共识肝病

世界卫生组织慢性乙型肝炎指南在埃塞俄比亚未能识别半数需要治疗的患者

The WHO guidelines for chronic hepatitis B fail to detect half of the patients in need of treatment in Ethiopia.
指南 / 共识 · J Hepatol · 2019-03-28

该研究在埃塞俄比亚1190例初治慢性乙型肝炎成人中评估WHO 2015指南治疗标准的诊断效能,以EASL 2017指南为金标准;WHO标准敏感性49.0%、特异性96.1%,仅识别出半数需要治疗的患者,作者认为需修订WHO治疗标准。

要点

  • 以EASL 2017为金标准,1190例中300例(25.2%)符合治疗条件,而WHO 2015标准仅识别182例(15.3%)。
  • WHO标准敏感性49.0%、特异性96.1%,漏诊约半数需要治疗的患者。
  • 符合WHO标准的182例中94例(51.6%)为失代偿期肝硬化,而115例代偿期肝硬化中仅41例(35.7%)符合WHO治疗标准。

核心结论

  • WHO慢性乙型肝炎指南在埃塞俄比亚未能识别半数需要治疗的患者,提示需修订WHO治疗标准。
  • 作者认为WHO标准可能不适合撒哈拉以南非洲。

研究设计与样本

  • 该研究为在埃塞俄比亚开展的队列分析,纳入在亚的斯亚贝巴公立慢性乙型肝炎门诊就诊的初治成人患者。
  • 所有患者招募时接受标准化评估,包括血液检查和瞬时弹性成像(Fibroscan®)。
  • 以Fibroscan >7.9 kPa定义显著纤维化,>9.9 kPa定义肝硬化。
  • 以EASL最新指南作为金标准评估治疗资格。
  • 共纳入1190例慢性乙型肝炎患者。

主要发现

  • 1190例中,基于EASL 2017指南300例(25.2%)符合治疗条件,基于WHO 2015指南182例(15.3%)符合治疗条件。
  • WHO标准的敏感性和特异性分别为49.0%和96.1%。
  • 符合WHO标准的182例中94例(51.6%)为失代偿期肝硬化。
  • 115例代偿期肝硬化患者中仅41例(35.7%)符合WHO标准治疗条件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: In 2015, the World Health Organization (WHO) issued guidelines for the management of chronic hepatitis B (CHB) in low- and middle-income countries, but little is known about the applicability of the WHO treatment criteria in sub-Saharan Africa. The aim of this study was to evaluate the diagnostic performance of the WHO guidelines in a large CHB cohort in Ethiopia. METHODS: Treatment-naïve adults who attended a public CHB clinic in Addis Ababa were included in this analysis. All patients underwent a standardized evaluation at recruitment, including blood tests and transient elastography (Fibroscan®). A Fibroscan result >7.9 kPa was used to define significant fibrosis and >9.9 kPa to define cirrhosis. Treatment eligibility was assessed using the most recent guidelines from the European Association for the Study of the Liver (EASL) as the 'gold standard'. RESULTS: Out of 1,190 patients with CHB, 300 (25.2%) were eligible for treatment based on the EASL 2017 guidelines and 182 (15.3%) based on the WHO 2015 guidelines. The sensitivity and specificity of the WHO criteria were 49.0 and 96.1%, respectively. Most patients (94 of 182; 51.6%) who fulfilled the WHO criteria had decompensated cirrhosis and might have a dismal prognosis even with therapy. Only 41 of 115 patients (35.7%) with compensated cirrhosis, who are likely to benefit the most from therapy, were eligible for treatment based on the WHO criteria. CONCLUSIONS: The WHO guidelines for CHB failed to detect half of the patients in need of treatment in Ethiopia, implying the need for a revision of the WHO treatment criteria. LAY SUMMARY: Antiviral therapy prevents disease progression and death in patients with chronic hepatitis B (CHB), but the identification of patients in need of treatment is a challenge in low- and middle-income countries. The World Health Organization (WHO) has suggested treatment eligibility criteria for use in such settings, but in our study the WHO criteria detected less than half of those in need of therapy in a large Ethiopian cohort of 1,190 patients with CHB. Our findings suggest that the WHO criteria might be unsuitable in sub-Saharan Africa. TRIAL REGISTRATION NUMBER: NCT02344498 (ClinicalTrials.gov identifier). Registered 16 January 2015.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Aberra H, Desalegn H, Berhe N, et al. The WHO guidelines for chronic hepatitis B fail to detect half of the patients in need of treatment in Ethiopia. J Hepatol. 2019. PMID: 30929749. doi:10.1016/j.jhep.2019.01.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。